Last reviewed · How we verify
Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents
Approved treatments
- Lopid · Pfizer Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents patent landscape — cliff calendar, originator estates, attackable patents
- Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents treatment landscape brief
- Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents treatment updates RSS
Frequently asked questions about Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents
What drugs treat Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents?
Tracked treatments include Lopid.
What is the treatment for Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents?
Standard treatment for Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents includes Lopid. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents patent cliff · Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents CI report
- Treatment: Lopid · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing